Prescriber's Corner

Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non–Small Cell Lung Cancer

Shan Li, PharmD, BCOP, and Eve M. Segal, PharmD, BCOP

University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Shan Li, PharmD, BCOP, Clinical Oncology Pharmacist, University of Washington Medical Center/Seattle Cancer Care Alliance, 825 Eastlake Avenue East, MS G5-900, Seattle, WA 98109. E-mail: shanli@seattlecca.org


J Adv Pract Oncol 2017;8:196–201 | https://doi.org/10.6004/jadpro.2017.8.2.7 | © 2017 Harborside Press®


  



For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.